 Home > Active Ingredient News > Antitumor Therapy > NEJM: ADC drug Sacituzumab govitecan first-line treatment of metastatic triple-negative breast cancer

NEJM: ADC drug Sacituzumab govitecan first-line treatment of metastatic triple-negative breast cancer

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

drug product

human epidermal growth factor

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Triple-negative breast cancer (TNBC) with negative expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2 ) accounts for about 15% of all breast cancers, of which metastatic three The survival prognosis of patients with negative breast cancer is poor.

Breast Cancer Immunity Researchers recently launched a phase III clinical study to investigate the therapeutic effect of Sacituzumab govitecan on patients with metastatic TNBC.

In this phase III clinical study, researchers compared Sacituzumab govitecan with first-line single-agent chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) for relapsed or refractory metastatic triple-negative breast cancer The treatment effect of the patient, chemotherapy drugs are selected by the clinician, and the patient has no brain metastasis.

468 patients participated in the study, including 235 patients in the Sacituzumab govitecan group and 233 patients in the first-line chemotherapy group.

The median progression-free survival in the Sacituzumab-govitecan group was 5.

Studies believe that for patients with metastatic triple-negative breast cancer who have previously been treated with paclitaxel, the ADC drug Sacituzumab-govitecan is superior to single-agent chemotherapy in terms of progression-free survival and overall survival, but adverse events of bone marrow suppression and diarrhea are more common.

For patients with metastatic triple-negative breast cancer who have previously been treated with paclitaxel, the ADC drug Sacituzumab-govitecan is superior to single-agent chemotherapy in terms of progression-free survival and overall survival, but adverse events of bone marrow suppression and diarrhea are more common.

Original source:

Aditya Bardia et al.

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancers.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.